Arrowhead Pharmaceuticals, a leader in RNAi therapeutics, reported a significant insider sale amid a year of exceptional stock gains.
Jan. 2, 2026, for a transaction value of ~$490,000 at a reported price of $35 per share. This disposition represented 7.79% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback